Commentary by Kathy Lee, Pharm.D. Pharmacy Practice Resident
On October 18 2007, the FDA announced the approval of labeling changes to erectile dysfunction (ED) drugs in the class known as phosphodiesterase type 5 (PDE-5) inhibitors. …
Category: Systems
Clinical Correlations
Class Act: Relieving the Obstruction – Surgical Approaches to the Management of Obstructive Sleep Apnea
October 18, 2007
Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. These posts focus on evidenced based answers to clinical questions related to patients seen by our …
Clinical Pharmacy Corner: How Do Sulfonylureas Work?
October 17, 2007Commentary by Helen Kourlas, PharmD and John Papadopoulas, PharmD, Pharmacology Section Editors
The sulfonylureas are members of a class of substituted arylsulfonylureas that have been used clinically since the 1950s. These agents are usually divided into two categories or generations. First generation agents include acetohexamide, chlorpropamide, tolazamide, and tolbutamide (the …
Inpatient Diabetes Management: Case 4
October 11, 2007
Commentary by Mary Vouyiouklis MD, Fellow, and Ann Danoff MD, Director, Division of Endocrinology, Diabetes and Metabolism, NYU Medical Center
Welcome to Case 4 of our special diabetes series intended to highlight the essentials …
Why Does Hypertriglyceridemia Lead to Pancreatitis?
October 4, 2007
Commentary by Daniel Frenkel, PGY-2
Case: A 46 year old male with diabetes on oral hypoglycemic medications is admitted to the hospital with one day of constant epigastric pain, nausea, vomiting, and an inability to tolerate oral intake. You …
Bedside Rounds: How Do You Diagnose and Treat Diabetic Neuropathy
October 3, 2007
Commentary by Judith Brenner MD, Associate Program Director, NYU Internal Medicine Residency Program
Diabetic neuropathy is one of the most commonly encountered complications of diabetes mellitus. It is seen in up …
Rifaximin: A useful drug for travelers’ diarrhea
September 28, 2007
Commentary by Sumathi Sivapalasingam MD, NYU Division of Infectious Diseases
Rifaximin is an oral semi-synthetic analog of rifampin which is essentially not absorbed (bioavailability <0.4%) making it useful for the treatment of …
Inpatient Diabetes Management: Case 3
September 27, 2007
Commentary by Mary Vouyiouklis MD, Fellow, and Ann Danoff MD, Director, Division of Endocrinology, Diabetes and Metabolism, NYU Medical Center
Welcome to Case 3 of our special diabetes series intended to highlight the …